423 related articles for article (PubMed ID: 30825186)
21. Activation of phosphodiesterase 5 and inhibition of guanylate cyclase by cGMP-dependent protein kinase in smooth muscle.
Murthy KS
Biochem J; 2001 Nov; 360(Pt 1):199-208. PubMed ID: 11696008
[TBL] [Abstract][Full Text] [Related]
22. Influence of cell confluence on the cAMP signalling pathway in vascular smooth muscle cells.
Belacel-Ouari M; Zhang L; Hubert F; Assaly R; Gerbier R; Jockers R; Dauphin F; Lechêne P; Fischmeister R; Manoury B; Leblais V
Cell Signal; 2017 Jul; 35():118-128. PubMed ID: 28389413
[TBL] [Abstract][Full Text] [Related]
23. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
Cheng J; Grande JP
Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
[TBL] [Abstract][Full Text] [Related]
24. Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum.
Gopal VK; Francis SH; Corbin JD
Eur J Biochem; 2001 Jun; 268(11):3304-12. PubMed ID: 11389733
[TBL] [Abstract][Full Text] [Related]
25. Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.
Keravis T; Lugnier C
Br J Pharmacol; 2012 Mar; 165(5):1288-305. PubMed ID: 22014080
[TBL] [Abstract][Full Text] [Related]
26. Cross-regulation of intracellular cGMP and cAMP in cultured human corpus cavernosum smooth muscle cells.
Kim NN; Huang Y; Moreland RB; Kwak SS; Goldstein I; Traish A
Mol Cell Biol Res Commun; 2000 Jul; 4(1):10-4. PubMed ID: 11152621
[TBL] [Abstract][Full Text] [Related]
27. Cyclic nucleotide phosphodiesterases in rabbit detrusor smooth muscle.
Qiu Y; Kraft P; Craig EC; Liu X; Haynes-Johnson D
Urology; 2002 Jan; 59(1):145-9. PubMed ID: 11796312
[TBL] [Abstract][Full Text] [Related]
28. Rabbit corpus cavernosum smooth muscle shows a different phosphodiesterase profile than human corpus cavernosum.
Qiu Y; Kraft P; Lombardi E; Clancy J
J Urol; 2000 Sep; 164(3 Pt 1):882-6. PubMed ID: 10953172
[TBL] [Abstract][Full Text] [Related]
29. Thrombospondin-1 inhibition of vascular smooth muscle cell responses occurs via modulation of both cAMP and cGMP.
Yao M; Roberts DD; Isenberg JS
Pharmacol Res; 2011 Jan; 63(1):13-22. PubMed ID: 20971192
[TBL] [Abstract][Full Text] [Related]
30. Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II.
Mokni W; Keravis T; Etienne-Selloum N; Walter A; Kane MO; Schini-Kerth VB; Lugnier C
PLoS One; 2010 Dec; 5(12):e14227. PubMed ID: 21151982
[TBL] [Abstract][Full Text] [Related]
31. Expression and activity of cGMP-dependent phosphodiesterases is up-regulated by lipopolysaccharide (LPS) in rat peritoneal macrophages.
Witwicka H; Kobiałka M; Siednienko J; Mitkiewicz M; Gorczyca WA
Biochim Biophys Acta; 2007 Feb; 1773(2):209-18. PubMed ID: 17141339
[TBL] [Abstract][Full Text] [Related]
32. PDE2 at the crossway between cAMP and cGMP signalling in the heart.
Weber S; Zeller M; Guan K; Wunder F; Wagner M; El-Armouche A
Cell Signal; 2017 Oct; 38():76-84. PubMed ID: 28668721
[TBL] [Abstract][Full Text] [Related]
33. "cAMP-specific" phosphodiesterase contributes to cGMP degradation in cerebellar cells exposed to nitric oxide.
Bellamy TC; Garthwaite J
Mol Pharmacol; 2001 Jan; 59(1):54-61. PubMed ID: 11125024
[TBL] [Abstract][Full Text] [Related]
34. Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. A study with selective inhibitors.
Schoeffter P; Lugnier C; Demesy-Waeldele F; Stoclet JC
Biochem Pharmacol; 1987 Nov; 36(22):3965-72. PubMed ID: 2825708
[TBL] [Abstract][Full Text] [Related]
35. Cyclic AMP-specific and cyclic GMP-specific phosphodiesterase isoenzymes in human cavernous arteries--immunohistochemical distribution and functional significance.
Waldkirch E; Uckert S; Yildirim H; Sohn M; Jonas U; Stief CG; Andersson KE; Hedlund P
World J Urol; 2005 Dec; 23(6):405-10. PubMed ID: 16292559
[TBL] [Abstract][Full Text] [Related]
36. Development of Phosphodiesterase-Protein-Kinase Complexes as Novel Targets for Discovery of Inhibitors with Enhanced Specificity.
Tulsian NK; Sin VJ; Koh HL; Anand GS
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34063491
[TBL] [Abstract][Full Text] [Related]
37. Myocardial Phosphodiesterases and Their Role in cGMP Regulation.
Dunkerly-Eyring B; Kass DA
J Cardiovasc Pharmacol; 2020 Jun; 75(6):483-493. PubMed ID: 31651671
[TBL] [Abstract][Full Text] [Related]
38. Effects of various phosphodiesterase-inhibitors, forskolin, and sodium nitroprusside on porcine detrusor smooth muscle tonic responses to muscarinergic stimulation and cyclic nucleotide levels in vitro.
Truss MC; Uckert S; Stief CG; Kuczyk M; Schulz-Knappe P; Forssmann WG; Jonas U
Neurourol Urodyn; 1996; 15(1):59-70. PubMed ID: 8696357
[TBL] [Abstract][Full Text] [Related]
39. Resistance to the nitric oxide/cyclic guanosine 5'-monophosphate/protein kinase G pathway in vascular smooth muscle cells from the obese Zucker rat, a classical animal model of insulin resistance: role of oxidative stress.
Russo I; Del Mese P; Doronzo G; Mattiello L; Viretto M; Bosia A; Anfossi G; Trovati M
Endocrinology; 2008 Apr; 149(4):1480-9. PubMed ID: 18079207
[TBL] [Abstract][Full Text] [Related]
40. Identification of substrate specificity determinants in human cAMP-specific phosphodiesterase 4A by single-point mutagenesis.
Richter W; Unciuleac L; Hermsdorf T; Kronbach T; Dettmer D
Cell Signal; 2001 Mar; 13(3):159-67. PubMed ID: 11282454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
